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Abstract  
 
Objectives 
To assess the clinical effectiveness, in acute ischemic stroke patients, of bypassing non-specialist 
centres in preference for a specialist stroke centre to receive the time critical intervention of 
thrombolysis. 
Methods 
Systematic review and meta-analysis using: MEDLINE; MEDLINE In-Process; EMBASE; 
CINAHL; Cochrane Library including Cochrane Database of Systematic Reviews, Cochrane 
CENTRAL Controlled Trials Register, DARE, NHS EED and HTA databases. Studies were 
included if they compared acute ischaemic stroke patients directly triaged to a Specialist Centre 
(SC) versus those initially triaged to a Non Specialist Centre (NSC) with some or all later 
transferred to a SC. Studies were excluded if they compared patients ever treated in a SC versus 
those never treated in a SC, since the aim was to assess the optimum initial triage route rather than 
the optimum location for overall management. The assumption being, based on previous research, 
that management in a SC leads to better patient outcomes. 
Results 
Fourteen studies investigating 2,790 patients were identified. Studies comparing commencement of 
thrombolysis in non-specialist centres versus the specialist centres (n=1394) showed no significant 
difference in unadjusted mortality (OR=0.89; 95% CI=0.61 to 1.30) or morbidity (favorable 
modified Rankin Score, N=899) (OR=1.16; 95% CI=0.85 to 1.59) among thrombolysed patients. In 
studies where thrombolysis could only be administered in a specialist centre, data for patients 
arriving within the therapeutic window (N=140) revealed significantly higher mortality for those 
initially admitted to a non-specialist centre compared to directly admitted to a specialist centre 
(OR=6.62; 95% CI=2.60 to 16.82); morbidity data also favored direct admission to a specialist 
centre, although not consistently. 
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Conclusions 
For ischaemic stroke patients, the location of initial thrombolysis treatment does not affect 
outcomes. However, if thrombolysis is only available at a specialist centre, outcomes are 
considerably better for those patients admitted directly. However, these conclusions are based on 
poor quality data with small sample populations, significant heterogeneity and subject to 
confounding. 
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Introduction 
In two reports for the UK Department of Health, the argument is made for the development of 
specialist stroke units to which stroke patients are transferred directly by the ambulance service to 
receive their care.1;2 The background to this is the increasing body of evidence for early 
interventional therapy, predominantly thrombolysis,3-5 and the coordinated care during 
rehabilitation that specialist units are able to provide. Outcomes from such services are consistently 
better than those reported for conventional medical ward treatment.6  
In the National Institute for Health and Clinical Excellence (NICE) guidelines7 the benefits of early 
PDQDJHPHQWDW µDFXWH¶ VWURNHXQLWVZHUH supported by the expert panel consensus opinion. These 
guidelines concluded with a recommendation that all people with suspected stroke should be 
admitted directly to a specialist centre (SC) following initial assessment either from the community 
or emergency department. They also concluded that CT scans performed as early as possible 
provided the most cost-effective management strategy. With these conclusions and evidence that 
thrombolysis within 90 minutes is better than beyond this time,5 one option to improve outcomes 
may be the administration of thrombolysis in the local emergency department, prior to subsequent 
appropriate transfer to a regional specialist centre.  
The 2009 Cochrane review on thrombolysis4 concluded that further trials were needed to identify 
the environment in which thrombolysis may best be given in routine practice. The key factor in 
improving outcomes in the initial phase of care appears to be the ability to deliver thrombolysis, but 
there is conflicting evidence about where it should be delivered to achieve the best outcomes. The 
latest stroke guidelines from the Royal College of Physicians8 recommends the commissioning of 
services to deliver all acute stroke patients to a specialised hyper-acute stroke unit. This should be 
done within one hour but the guidelines accept that ³(PHUJHQF\ PHGLFDO VWDII LI DSSURSULDWHO\
trained and supported, can administer alteplase for the treatment of acute ischaemic stroke provided 
that patients can be managed within an acute service with appropriate neuro-radiological and stroke 
SK\VLFLDQVXSSRUW´ 
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A systematic review was undertaken to assess the clinical effectiveness, in acute ischaemic stroke 
patients, of choosing to bypass a local non-specialist hospital in preference for a specialist stroke 
centre to receive the time-critical intervention of thrombolysis. Throughout this review the 
evidence-based assumption that care within a specialist stroke centre leads to better outcomes for 
stroke patients has been made. 
 
Methods 
A systematic review was undertaken according to the general principles recommended in the 
PRISMA statement9 (Appendix I). 
Search strategy 
The following databases were searched: MEDLINE; MEDLINE In-Process; EMBASE; CINAHL; 
Cochrane Library including Cochrane Database of Systematic Reviews, Cochrane CENTRAL 
Controlled Trials Register, DARE, NHS EED and HTA databases. Searches were undertaken 
between August and December 2010, and updated in December 2012 following recommendations 
from peer review of a previously submitted article and report. An initial search was conducted, and 
inspection of retrieved articles generated further relevant search terms that were used in an 
additional search. The search was limited to articles published in English from 1988 onwards, due 
to changes in organization of emergency care over time. The Search Strategies are included as 
Appendix II. 
A title and initial abstract sift were undertaken by two reviewers (SH/KC), with involvement of a 
third reviewer where necessary (AP). Potentially relevant articles were then fully screened by two 
reviewers (SH/KC) and any uncertainties resolved through discussion with a third reviewer (AP). 
Data were extracted by one reviewer and checked by a second. 
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Inclusion criteria 
Patients presenting with ischemic stroke were included because its management has a time-critical 
element (administration of thrombolytic therapy).5;10 Studies of haemorrhagic stroke were excluded 
since its management does not have such a clear time-critical treatment strategy. The intervention 
assessed was a policy of direct triage to a SC bypassing local hospitals. The comparator was initial 
admission to a non-specialist centre (NSC) such as a local hospital, with potential for later transfer 
to a SC if indicated due to the condition and severity. Studies where transfer was not possible were 
excluded. 
Relevant outcomes included mortality and morbidity based on validated measures. The review 
protocol specified the outcome of mortality measured at three time points: prehospital, 7 and 30 
days postevent. In a change to the protocol, due to lack of available data at the prespecified time 
points, mortality was included at any time point, and these data are represented in the forest plots 
included. The two morbidity scales used were the modified Rankin Scale (mRS)11 and the National 
Institute for Health Stroke Scale (NIHSS) 12 as these were the most commonly reported in the 
literature. The mRS is an ordinal scale that categorises patients from 0 (no symptoms) to 6 (dead) 
with 1-5 being different levels of function and independence.  The NIHSS scale was developed to 
grade stroke severity with lower scores representing less severe disease. Time to thrombolysis has 
been included where the data was able to be extracted. 
Studies were included if they compared patients directly triaged to a SC versus those initially 
triaged to a NSC with some or all later transferred to a SC. Studies were excluded if they compared 
patients ever treated in a SC versus those never treated in a SC, since the aim was to assess the 
optimum initial triage route rather than the optimum location for overall management. Studies 
where the pathway of care was uncertain were considered at full-text review and excluded if no data 
could be extracted to contribute to the analysis based on consensus opinion of all reviewers. 
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Data synthesis 
Data were meta-analysed using Review Manager version 5.0.13 Random effects models were used 
where clinical, methodological or statistical heterogeneity14 existed between studies. Clinical 
heterogeneity existed where studies evaluated different components of the care pathway or different 
patient groups within their potential cohort. Where random effects models were not used the results 
are presented by subgrouping similar studies. Data were converted so all odds ratios (ORs) 
compared initial triage to NSCs versus direct admission to SCs; similarly, ORs for survival were 
converted to mortality. Hence for the presented mortality data a higher OR favours direct admission 
to SCs, whilst for morbidity data (reporting on favourable outcomes) a lower OR favours SCs. 
Risk of bias assessment 
Risk of bias within included studies was assessed using criteria developed for this review, based on 
the Cochrane Handbook,14 the Critical Appraisal Skills Programme (CASP) checklist for cohort 
studies,15 the Downs & Black checklist for study quality,16 and the Newcastle-Ottowa scale.17 
Criteria that assessed potential for bias in study design, rather than quality of reporting, were 
selected. No criteria are reported here relating to validity of outcome measures (since this review 
used prespecified, standard outcomes such as mortality and validated morbidity measures) or to 
blinding as the primary outcome was mortality. However, the subjective nature of the morbidity 
tools used would warrant an assessment of blinding and this LVH[SDQGHGXSRQLQµ5HVXOWV¶VHFWLRQ 
The selected criteria covered four key areas: 
1. Comparability between groups: Risk of bias due to the lack of inclusion of, or 
adjustment for, NSC patients not transferred to SC. 
2. Adjustment: Risk of bias due to lack of adjustment of analyses for differences in age and 
severity between groups. 
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3. Representative sample: Risk of bias due to selection of patients based on condition 
subtype or interventions received. 
4. Exclusions: Risk of bias due to more than 5% patients excluded due to missing data. 
 
Results 
Studies included 
The review identified fourteen relevant studies (within 15 references).18-32 (Study characteristics ±
Appendix III). Only controlled cohort studies were identified. Seven studies were conducted in the 
USA,18;20;22-24;28;32 one in Taiwan,29 and five in Europe (three in Spain,26;27;30 one in Germany31 and 
one in France21).  The country was not reported in one study. 19 Two pairs of studies appeared to 
have overlapping cohorts. Silva 200922 recruited patients at the same time as Pervez 2010,20 partly 
in the same hospital, but for fewer years and has only been used in synthesis where outcomes were 
not reported for the larger cohort in Pervez 2010.20 Similarly, Ribo 200827 recruited patients at the 
same time as Perez de la Ossa 200926 and from the same region, but for fewer years and has only 
been used in synthesis where outcomes were not reported by Perez de la Ossa 2009. 
Study size ranged from 39 to 602 patients with a total of 2790 across all studies. SCs were 
described as stroke centres, stroke units or neurological units. NSCs were generally described as 
other hospitals or community hospitals, with some studies specifying that no specific stroke care 
was available.  
Eleven of the included studies were restricted to patients receiving thrombolysis, therefore did not 
capture effects on outcomes of differing thrombolysis rates between groups, which could be 
affected by the initial triage decision should the transfer take patients beyond the therapeutic 
window. The remaining three studies were not restricted to patients receiving thrombolysis but 
thrombolysis was only available for transfer patients at the SC if at all. The time to outcome 
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assessment for both mortality and morbidity data varied greatly, ranging from in-hospital to one 
year. These are embedded within the forest plots, listed next to each study author. 
Risk of bias 
Risk of bias in included studies is summarised in Appendix IV. All included studies compared 
patients transferred from NSC to SC versus those directly triaged to SC. No studies included or 
accounted for NSC patients who were not transferred to SC. Three studies adjusted at least one of 
their analyses for patient factors such as age and severity of injury, while the remainder were 
unadjusted. The between-group difference in baseline NIHSS varied across studies, sometimes 
being higher in transferred patients and sometimes in patients triaged direct to SC (Appendix III). 
The number of exclusions due to missing data was unclear for four studies while the remainder 
appeared to have no exclusions, although it was often unclear whether only patients with available 
data were included. 
All studies evaluated a selected subgroup of patients; no included studies assessed all ischaemic 
stroke patients. Studies were sub-grouped in terms of where thrombolysis was initiated for transfer 
patients, as described earlier. 
None of the prospective studies reported any blinding of outcome assessments to the method of 
delivery to the SC. The other studies were all retrospective with no reported consideration of 
blinding. 
 
Studies initiating thrombolysis in NSC prior to transfer (thrombolysed patients only) 
In seven studies restricted to thrombolysed patients only, transfer patients received thrombolysis in 
the NSC prior to transfer to the SC and were compared with patients taken directly to the SC for 
thrombolysis.18-23;32 Two studies had a likely overlap of included patients so only the most recent is 
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included in each analysis.20;22 In one further study (two references) 50% of transfer patients 
received thrombolysis in the SC and 50% in the NSC.24;25 
Four studies reported unadjusted mortality data (total N=1,394; Figure 1) showing no significant 
difference in the individual studies or the pooled analysis for initial triage to NSC vs. SC (OR 0.89, 
95% CI 0.61 to 1.30), with no heterogeneity between studies (I2=0%).18;20;21;32 A further study 
(N=220) in which transfer patients could receive thrombolysis in either the NSC or SC also showed 
no significant difference in mortality (OR 1.11, 95% CI 0.48 to 2.53).24;25 
Five studies reported data on the proportion of patients with a favourable modified Rankin Scale 
(mRS) the definition of which differed between studies, as did the time of outcome assessment. 
There was no significant difference between groups for one study adjusting for baseline 
characteristics (N=296; OR 0.92, 95% CI 0.65 to 1.30; Figure 2)20 or for four studies presenting 
unadjusted analyses (total N=899; pooled OR 1.16, 95% CI 0.85 to 1.59; Figure 3).19;21;22;32  
One study reported similar reductions in mean National Institute of Health Stroke Scale (NIHSS) 
score at follow-up in the two groups.23 Two studies, one in which transfer patients began 
thrombolysis in NSC and one in which transfer patients could receive thrombolysis in either the 
NSC or SC showed no significant difference between groups for the (unadjusted) proportion of 
patients with favourable NIHSS (score 0-5) at follow-up (Figure 4). Comparisons for transfer vs. 
direct triage to SC were OR 1.04 (95% CI 0.63 to 1.70, N=396) 32and OR 1.21 (95% CI 0.67 to 
2.19, N=220) 24;25 
Of the six studies reporting this outcome, three reported longer times to thrombolysis in the transfer 
group, 20;24;25;32 while three reported longer times in the direct-to-SC group (Table 1).19;21;23 
 
11 
 
Studies initiating thrombolysis in SC after transfer (thrombolysed patients only) 
In three studies restricted to thrombolysed patients only, transfer patients began thrombolysis after 
transfer from NSC to SC; these were compared with patients triaged directly to the SC and 
receiving thrombolysis there.26-28 Two studies had a likely overlap of included patients so only the 
most recent is included in each analysis.26;27 
One study (N=72; Figure 1) showed no significant difference in (unadjusted) mortality for patients 
receiving thrombolysis after transfer vs. direct triage to SC; the small number of events in this study 
precludes firm conclusions (OR 0.68, 95% CI 0.13 to 3.67).28 
One study reported data on the proportion of patients with favourable mRS. This study significantly 
favoured direct triage to SC when adjusting for baseline characteristics. (N=153, OR 0.40, 95% CI 
0.17 to 0.94; Figure 2)26 and showed a non-significant trend in this direction for the unadjusted 
analysis (N=153; OR 0.70, 95% CI 0.35 to 1.41, Figure 3)  
Two studies reported unadjusted data on the proportion of patients with favourable or improved 
NIHSS (score 0-1 or improvement of 4 points) at follow-up. A meta-analysis of these two studies 
(total N=225; Figure 4) favoured direct triage to SC, though this was not statistically significant 
(OR 0.62, 95% CI 0.23 to 1.67).26;28  
Two studies reported longer times from onset to thrombolysis in the transfer groups than in the 
direct-to-SC groups (Table 1).26;28 
 
Studies initiating thrombolysis in SC after transfer (thrombolysed and non-thrombolysed 
patients) 
Three studies did not restrict recruitment to patients receiving thrombolysis. Of these, two included 
only patients arriving at the SC within the time window for thrombolysis (within 4-6 hours of onset 
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as defined by study protocol); the proportions receiving thrombolysis were 12% (12/101) overall in 
one study (not reported per group)29 with 27% (30/112) for transfers and 54% (31/57) for direct-to-
SC in the other study.30 The remaining study was restricted to patients with basilar artery occlusion, 
of whom 44% (7/16) of transfers and 48% (11/23) of those going direct to SC received 
thrombolysis.31 In all three studies, transfer patients only received thrombolysis at the SC if at all 
(not at the NSC). 
Two studies reported (unadjusted) mortality (total N=140; Figure 1); both significantly favoured 
direct triage to SC, with a pooled OR for mortality for transfers versus direct triage of 6.62 (95% CI 
2.60 to 16.82).29;31 
Two studies presented data on the proportion of patients with favourable mRS again with different 
definitions and time of assessment. One study adjusting for baseline characteristics favoured direct 
triage to SC (N=169; OR 0.34, 95% CI 0.15 to 0.77; Figure 2).30 In unadjusted analyses, this study 
no longer showed a significant effect,30 while the other study31 significantly favoured direct triage 
to SC. Pooled analysis of these studies showed a non-significant trend favouring direct triage (total 
N=208; OR 0.29, 95% CI 0.02 to 4.28; Figure 3). 
One study presenting data on the (unadjusted) proportion of patients with favourable or improved 
NIHSS (score 0-1 or improvement of 4 points) at follow-up significantly favoured direct triage to 
SC (N=169; OR 0.38, 95% CI 0.20 to 0.74; Figure 4).30  
One study reported time from onset to thrombolysis, showing a longer time in the transfer group 
than in the direct-to-SC group (Table 1).30 
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Discussion 
Principal findings 
In studies where transfer patients were able to begin thrombolysis in a non-specialist centre (NSC) 
prior to transfer, mortality rates were no different to those patients triaged directly to the specialist 
centre (SC). There was also no difference in the proportion of patients with favourable morbidity 
outcomes at follow-up. These findings suggest that commencing thrombolysis for eligible patients 
in a local NSC can be as effective as if delivered in a regional SC within the context of the 
limitations identified below.  
Studies in which transfer patients only began thrombolysis after transfer from NSC to SC can be 
divided into studies restricted to thrombolysed patients only and studies assessing all stroke 
patients. In both, outcomes (mortality, follow-up mRS and NIHSS scores) were generally better for 
patients triaged direct to SC; this was statistically significant in three analyses.  
 
Strengths and weaknesses of this study 
We focused on thrombolysis, a validated treatment available for long enough to generate sufficient 
evidence to enable analysis. It is recognised that there are more interventional treatments available 
and being developed for the management of acute stroke, many only available in specialist stroke 
centres.  
Only three of the fourteen studies identified adjusted for age, co-morbidities or severity and these 
were only for morbidity data. The lack of adjustment could significantly influence outcome 
comparisons ± in particular mortality rates ± as the lack of transfer decision randomization 
introduces the potential for both selection and allocation bias leading to significant differences 
between the NSC and SC groups. Most studies were restricted to thrombolysed patients and have 
not captured differences in outcome due to thrombolysis rate variability. Only one study reported 
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this data and described a two-fold treatment rate difference,30 which could significantly affect 
between-group comparison of outcomes. The higher treatment rate identified in the direct group 
could be considered an outcome in itself but the study does not report the number of patients 
delivered to the NSC who may have been eligible for treatment if taken directly to the SC.  
Implications for policy 
The poor quality of data identified highlights the lack of evidence available to support the current 
consensus recommendations for direct transfer of all suspected stroke patients to a specialist acute 
stroke unit.8 However, the idea suggested from our results that delivery of all stroke patients to the 
nearest NSC is as effective as direct transfer to the SC cannot be supported. The restricted cohorts 
identified for this review limit the generalisability of our findings and, as such, must be interpreted 
with caution. This review found no evidence to contradict the current guidelines for the 
commissioning of stroke services in England. 8  
Future research 
The studies identified for this review do not include a comprehensive enough cohort of patients to 
justify any clear conclusions, with questions remaining about the outcomes for non-thrombolysed 
patients in either arm, the impact of triage decisions on treatment rates in appropriate patients and 
the relevance of the time frame for outcome assessments. 
When assessing the impact of an early intervention, such as triage to the most appropriate centre, 
the earlier the outcome is assessed the less likely that confounding factors can influence results. 
Future research should focus on a whole system approach, from the point of symptom onset, and 
include all suspected stroke patients managed within a network of receiving centres. In our review 
half of the included studies (n=7) mentioned telephone and/or telemedicine contact between NSC 
and SC which may have facilitated the initiation of treatment prior to SC arrival. Future work 
should also include both short and long-term outcomes in order to differentiate the benefit of correct 
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triage decisions from the recognised benefits of early, focused rehabilitation and high quality 
multidisciplinary care delivered in a specialist stroke centre.  
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Table 1. Time and distance data 
Study Country (area) Distances Mean / 
median 
Time from onset to thrombolysis (mins) 
Transferred 
patients (B) 
Direct to SC 
patients (A) 
Difference: B 
minus A 
Thrombolysed only (transfers had tPA in NSC) 
Rodriguez 201218 USA (Minnesota) NR  NR NR NR 
Hsia 201119 Country NR NR Mean (SD) 146 (39) 157 (24) -11 
Martin-Schild 
201132 
USA (Houston, Texas) Area covering more than 100 mile radius. 
Mean distance 77 (SD45) miles (includes 
patients with >3 hour treatment time) 
Median 
(IQR) 
150 (117-165) 135 (105-
157) 
15 
Pervez 201020 USA (Boston, 
Massachusetts) 
Distance NSC to SC: median 43 miles (IQR 
17-58) 
Median 
(IQR) 
140 (117-165) 130 (103-
163) 
10 
Allibert 200921 France (Besancon) NR Median 156 217 -61 
Wang 200023 USA (Illinois counties) Network: 23 counties inc. small towns. 
Distance NSC to SC: range 0.25-130 miles 
Mean (SD) 141 (52) 155 (53) -14 
Thrombolysed only (transfers had tPA in NSC or SC) 
Rymer 2005,24 
Rymer 200425 
USA (Kansas City, 
Missouri) 
Metropolitan area. 150 miles maximum 
distance. 
Mean (SD) 213 (117) 182 (110) 31 
Thrombolysed only (transfers had tPA in SC) 
Perez de la Ossa 
200926 
Spain (Barcelona) Metropolitan area. 80km maximum 
distance. 
Median 
(IQR) 
165 (140-179) 135 (105-
162) 
30 
Merino 200228 USA (London, 
Ontario) 
Area covers 7 counties over 7800 square 
miles. Distance NSC to SC: mean 41 miles 
(range 11-80) 
Mean 
(range) 
172 (135-203) 148 (69-191) 24 
Some thrombolysed, arrived at SC within 4-6h of onset in 2 of 3 studies (transfers had tPA in SC if at all) 
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Study Country (area) Distances Mean / 
median 
Time from onset to thrombolysis (mins) 
Transferred 
patients (B) 
Direct to SC 
patients (A) 
Difference: B 
minus A 
Li 200829 Taiwan (Kaohsiung) NR  NR   
Perez de la Ossa 
200830 
Spain (Barcelona) Metropolitan area. 80km maximum distance Median 
(IQR) 
165 (135-179) 125 (100-
157) 
40 
Muller 200731 Germany (Munich & 
Regensburgh) 
NR  NR   
Abbreviations: IQR=interquartile range; NR=not reported; NSC=non-specialist centre; SC=specialist centre; SD=standard deviation; tPA=tissue plasminogen activator (thrombolysis). 
 Definitions of study groups: A=direct to SC and remained there;; B=to NSC initially then transferred to SC. 
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Figure 1. Unadjusted mortality for transfer NSC to SC vs. direct to SC, sub-
grouped by thrombolysis setting 
Study or Subgroup
1.1.1 Thrombolysed only; transfers had tPA in NSC
Rodriguez 2012 (in-hosp)
Martin-Schild 2011 (hosp)
Pervez 2010 (in-hosp)
Allibert 2009 (3m)
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 1.84, df = 3 (P = 0.61); I² = 0%
Test for overall effect: Z = 0.60 (P = 0.55)
1.1.3 Thrombolysed only; transfers had tPA in NSC or SC
Rymer 2005 (in-hosp)
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
1.1.4 Thrombolysed only; transfers had tPA in SC
Merino 2002 (3m)
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
1.1.5 Some thrombolysed; transfers had tPA in SC if at all
Li 2008 (in-hosp)
Muller 2007 (1y)
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.43, df = 1 (P = 0.51); I² = 0%
Test for overall effect: Z = 3.97 (P < 0.0001)
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.35; Chi² = 17.88, df = 7 (P = 0.01); I² = 61%
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Chi² = 15.63, df = 3 (P = 0.001), I² = 80.8%
Events
9
9
27
7
52
25
25
2
2
7
13
20
99
Total
129
84
181
46
440
158
158
23
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16
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32
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33
20
14
95
9
9
6
6
11
7
18
128
Total
473
312
115
54
954
62
62
49
49
85
23
108
1173
Weight
15.1%
15.1%
16.9%
12.5%
59.6%
14.6%
14.6%
7.0%
7.0%
10.8%
7.9%
18.8%
100.0%
M-H, Random, 95% CI
1.19 [0.55, 2.59]
1.01 [0.47, 2.21]
0.83 [0.44, 1.57]
0.51 [0.19, 1.41]
0.89 [0.61, 1.30]
1.11 [0.48, 2.53]
1.11 [0.48, 2.53]
0.68 [0.13, 3.67]
0.68 [0.13, 3.67]
5.23 [1.62, 16.92]
9.90 [2.13, 46.10]
6.62 [2.60, 16.82]
1.30 [0.76, 2.24]
Year
2012
2011
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2009
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2002
2008
2007
TRANSFERS DIRECT Odds Ratio Odds Ratio
M-H, Random, 95% CI
0.02 0.1 1 10 50
Favours TRANSFERS Favours DIRECT
 
Time of outcome measurement is shown for each study following author/date. 
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Figure 2. Favourable mRS at follow-up (<1 or <2; adjusted analysis) for transfer 
NSC to SC vs. direct to SC  
Study or Subgroup
1.2.1 Thrombolysed only; transfers had tPA in NSC
Pervez 2010 (1 yr)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
1.2.2 Thrombolysed only; transfers had tPA in SC
Perez de la Ossa 2009 3m
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.10 (P = 0.04)
1.2.3 Some thrombolysed; transfers had tPA in SC if at all
Perez de la Ossa 2008hosp
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.58 (P = 0.010)
Total (95% CI)
Heterogeneity: Tau² = 0.28; Chi² = 6.95, df = 2 (P = 0.03); I² = 71%
Test for overall effect: Z = 1.67 (P = 0.09)
Test for subgroup differences: Chi² = 6.95, df = 2 (P = 0.03), I² = 71.2%
log[Odds Ratio]
-0.0834
-0.9163
-1.0788
SE
0.1772
0.4366
0.4175
Total
181
181
45
45
112
112
338
Total
115
115
108
108
57
57
280
Weight
42.6%
42.6%
28.2%
28.2%
29.2%
29.2%
100.0%
IV, Random, 95% CI
0.92 [0.65, 1.30]
0.92 [0.65, 1.30]
0.40 [0.17, 0.94]
0.40 [0.17, 0.94]
0.34 [0.15, 0.77]
0.34 [0.15, 0.77]
0.54 [0.27, 1.11]
Year
2010
2009
2008
TRANSFERS DIRECT Odds Ratio Odds Ratio
IV, Random, 95% CI
0.01 0.1 1 10 100
Favours DIRECT Favours TRANSFERS
 
Time of outcome measurement is shown for each study following author/date. 
22 
 
Figure 3. Favourable mRS at follow-up (<1, <2 or <3; unadjusted analysis) for 
transfer NSC to SC vs. direct to SC 
Study or Subgroup
1.3.1 Thrombolysed only; transfers had tPA in NSC
Martin-Schild 2011 (hosp)
Hsia 2011 (in-hosp)
Allibert 2009 (3m)
Silva 2009 (6m)
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.65, df = 3 (P = 0.88); I² = 0%
Test for overall effect: Z = 0.95 (P = 0.34)
1.3.3 Thrombolysed only; transfers had tPA in SC
Perez de la Ossa 2009 3m
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
1.3.4 Some thrombolysed; transfers had tPA in SC if at all
Perez de la Ossa 2008hosp
Muller 2007 (1y)
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 3.17; Chi² = 5.70, df = 1 (P = 0.02); I² = 82%
Test for overall effect: Z = 0.90 (P = 0.37)
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.06; Chi² = 8.97, df = 6 (P = 0.18); I² = 33%
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Chi² = 2.57, df = 2 (P = 0.28), I² = 22.2%
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39
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27
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24
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1
52
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Total
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Total
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Weight
23.0%
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12.4%
11.0%
66.0%
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16.9%
2.2%
19.1%
100.0%
M-H, Random, 95% CI
1.20 [0.74, 1.94]
1.32 [0.75, 2.33]
0.90 [0.41, 2.02]
1.04 [0.44, 2.49]
1.16 [0.85, 1.59]
0.70 [0.35, 1.41]
0.70 [0.35, 1.41]
0.93 [0.49, 1.76]
0.06 [0.01, 0.54]
0.29 [0.02, 4.28]
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Time of outcome measurement is shown for each study following author/date. 
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Figure 4. Favourable or improved NIHSS at follow-up (unadjusted analysis) for 
transfer NSC to SC vs. direct to SC 
Study or Subgroup
1.4.1 Thrombolysed only; transfers had tPA in NSC
Martin-Schild 2011 (24h)
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
1.4.2 Thrombolysed only; transfers had tPA in NSC or SC: NIHSS 0-5
Rymer 2005 (in-hosp)
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
1.4.3 Thrombolysed only; transfers had tPA in SC: NIHSS 0-1 or improvement of 4
Perez de la Ossa 2009 24h
Merino 2002 (3m)
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.28; Chi² = 2.12, df = 1 (P = 0.15); I² = 53%
Test for overall effect: Z = 0.94 (P = 0.35)
1.4.6 Some thrombolysed; transfers had tPA in SC if at all: NIHSS 0-1 or improvement of 4
Perez de la Ossa 2008 24h
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 2.88 (P = 0.004)
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.21; Chi² = 11.37, df = 4 (P = 0.02); I² = 65%
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Chi² = 8.08, df = 3 (P = 0.04), I² = 62.9%
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Weight
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Time of outcome measurement is shown for each study following author/date. 
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Appendix I: PRISMA checklist 
 
Section/topic Item No Checklist item Reported on page 
No 
Title 
Title 1 Identify the report as a systematic review, meta-analysis, 
or both 
1 
Abstract 
Structured 
summary 
2 Provide a structured summary including, as applicable, 
background, objectives, data sources, study eligibility 
criteria, participants, interventions, study appraisal and 
synthesis methods, results, limitations, conclusions and 
implications of key findings, systematic review 
registration number 
 
2 
Introduction 
Rationale 3 Describe the rationale for the review in the context of what 
is already known 
4 
Objectives 4 Provide an explicit statement of questions being addressed 
with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS) 
5 
Methods 
Protocol and 
registration 
5 Indicate if a review protocol exists, if and where it can be 
accessed (such as web address), and, if available, provide 
registration information including registration number 
 6  
Eligibility criteria 6 Specify study characteristics (such as PICOS, length of 
follow-up) and report characteristics (such as years 
considered, language, publication status) used as criteria 
for eligibility, giving rationale 
6 
Information 
sources 
7 Describe all information sources (such as databases with 
dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched 
5 
Search 8 Present full electronic search strategy for at least one 
database, including any limits used, such that it could be 
repeated 
Appendix II 
Study selection 9 State the process for selecting studies (that is, screening, 
eligibility, included in systematic review, and, if 
applicable, included in the meta-analysis) 
5 
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Section/topic Item No Checklist item Reported on page 
No 
Data collection 
process 
10 Describe method of data extraction from reports (such as 
piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from 
investigators 
5 
Data items 11 List and define all variables for which data were sought 
(such as PICOS, funding sources) and any assumptions 
and simplifications made 
 
6 
Risk of bias in 
individual studies 
12 Describe methods used for assessing risk of bias of 
individual studies (including specification of whether this 
was done at the study or outcome level), and how this 
information is to be used in any data synthesis 
 
7 
Summary 
measures 
13 State the principal summary measures (such as risk ratio, 
difference in means). 
7 
Synthesis of 
results 
14 Describe the methods of handling data and combining 
results of studies, if done, including measures of 
consistency (such as I2 statistic) for each meta-analysis 
 
7 
Risk of bias 
across studies 
15 Specify any assessment of risk of bias that may affect the 
cumulative evidence (such as publication bias, selective 
reporting within studies) 
N/A 
Additional 
analyses 
16 Describe methods of additional analyses (such as 
sensitivity or subgroup analyses, meta-regression), if done, 
indicating which were pre-specified 
7 
Results 
Study selection 17 Give numbers of studies screened, assessed for eligibility, 
and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram 
8 
Study 
characteristics 
18 For each study, present characteristics for which data were 
extracted (such as study size, PICOS, follow-up period) 
and provide the citations 
Appendix III 
Risk of bias 
within studies 
19 Present data on risk of bias of each study and, if available, 
any outcome-level assessment (see item 12). 
Appendix IV 
Results of 
individual studies 
20 For all outcomes considered (benefits or harms), present 
for each study (a) simple summary data for each 
intervention group and (b) effect estimates and confidence 
intervals, ideally with a forest plot 
 
Figures 1-4 
Synthesis of 
results 
21 Present results of each meta-analysis done, including 
confidence intervals and measures of consistency 
Figures 1-4 
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Section/topic Item No Checklist item Reported on page 
No 
Risk of bias 
across studies 
22 Present results of any assessment of risk of bias across 
studies (see item 15) 
N/A 
Additional 
analysis 
23 Give results of additional analyses, if done (such as 
sensitivity or subgroup analyses, meta-regression) (see 
item 16) 
Figures 1-4 
Discussion 
Summary of 
evidence 
24 Summarise the main findings including the strength of 
evidence for each main outcome; consider their relevance 
to key groups (such as health care providers, users, and 
policy makers) 
13 
Limitations 25 Discuss limitations at study and outcome level (such as 
risk of bias), and at review level (such as incomplete 
retrieval of identified research, reporting bias) 
13 
Conclusions 26 Provide a general interpretation of the results in the 
context of other evidence, and implications for future 
research 
14 
Funding 
Funding 27 Describe sources of funding for the systematic review and 
other support (such as supply of data) and role of funders 
for the systematic review 
15 
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Appendix II: Literature search strategies 
Due to the complex, multi-faceted nature of the research question, an iterative approach to the searches was 
taken. Below is an example of the initial search strategy (1.1) performed in MEDLINE.  This was developed 
IROORZLQJDVFRSLQJVHDUFKDQGXVLQJ³VQRZEDOOLQJ´E\FRQVXOWLQJWKHLQGH[LQJDQGNH\ZRUGVRINH\SDSHUV
identified by experts.  This initial MEDLINE search was adapted for the other electronic databases 
accordingly. 
MEDLINE search strategies 
Search 1.1: Initial search for clinical review 
Key: $=truncation; */=medical subject heading. 
1     (hospital$ adj bypass$).mp. 
2     (direct adj1 transfer$).mp.  [changed from (direct adj transfer$) following scoping search and analysis 
of papers identified by experts] 
3     (bypass adj protocol$).mp. 
4     *Trauma Centers/  
5     trauma system$.ti,ab.  
6     (trauma centre$ or trauma center$).ti.  
7     (prehospital adj trauma adj triage).mp.  
8     (tertiary adj trauma adj cent$).mp.  
9     (pre-hospital adj trauma adj triage).mp.  
10     (prehospital$ or pre-hospital$).ti.  
11     (ambulance$ and triage).mp.  
12     *Ambulances/  
13     *Triage/  
14     12 and 13  
15     ((prehospital or pre-hospital) and triage and protocol$).mp.   [Note that the keyword triage is used in 
conjunction with other terms such as pre-hospital and trauma (steps 6-14) as using triage as an individual 
term was considered too broad, adding an additional 964 references to the MEDLINE search alone.  These 
were checked and considered not relevant.] 
16     regionali?ation.ti,ab.  
17     *Delayed Diagnosis/  
18     "Transportation of Patients"/ae, ec  [Removed *focusing of MeSH heading following scoping search 
and analysis of papers identified by experts] 
19     "Transportation of Patients"/st, ut  [Additional sub-headings added following scoping search and 
analysis of papers identified by experts] 
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20     Patient Transfer/ec, mt, og, st, ut, sn [Economics, Methods, Organization & Administration, Standards, 
Utilization]  [Removed *focusing of MeSH heading in conjunction with subheadings following scoping 
search and analysis of papers identified by experts] 
21     *Patient Transfer/  [Focused MeSH heading without subheadings following scoping search and 
analysis of papers identified by experts] 
[Terms 1-21 identified in scoping of the literature and consultation with project team] 
22     (interhospital transfer$ or inter-hospital transfer$ or IHT).ti,ab.  
23     (direct adj1 (admitted or admission$)).ti,ab.  
24     (trauma care system$ or rapid transfer$ or integrated transfer system$).ti,ab.  
25     trauma care.ti.  [Terms 22-25 all added following scoping search and analysis of papers identified by 
experts] 
26     or/1-11 
27     polytrauma.ti,ab.  
28     multi-system trauma.ti,ab.  
29     multisystem trauma.ti,ab.  
30     major trauma.ti,ab.  
31     severe trauma.ti,ab.  
32     *Stroke/  
33     stroke$.ti,ab.  
34     *Cerebral Infarction/  
35     cerebral infarc$.ti,ab.  
36     cerebrovascular accident$.ti,ab.  
37     CVA.ti,ab.  
38     significant trauma.ti,ab.  
39     important trauma.ti,ab.  
40     *Craniocerebral Trauma/  
41     head injur$.ti,ab.  
42     craniocerebral trauma$.ti,ab.  
43     *Brain Injuries/  
44     brain injur$.ti,ab.  
45     (intra-cranial adj (haemorrhage or hemorrhage or bleed)).ti,ab.  
46     (intracranial adj (haemorrhage or hemorrhage or bleed)).ti,ab.  
47     *Intracranial Hemorrhages/ or *Cerebral Hemorrhage/ or *Subarachnoid Hemorrhage/  [Condition 
terms 27-47 identified by scoping the literature and consultation with the project team] 
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48     *Hematoma, Epidural, Cranial/  
49     severe emergenc$.ti,ab.  
50     *Critical Care/sn [Statistics & Numerical Data]  
51     or/14-24  
52     26 or 51  
53     severe traumatic injur$.ti,ab.  
54     severe$ injur$.ti.  
55     trauma patient$.ti.  
56     critical$ ill$.ti.  [Condition terms 48-56 added following scoping search and analysis of papers 
identified by experts] 
57     or/53-56  
58     Multiple Trauma/ec, th [Economics, Therapy]  
59     *Multiple Trauma/  
60     or/27-50  
61     or/58-59  
62     57 or 60 or 61  
63     52 and 62  
64     limit 63 to yr="1988 - 2010"  [Note that no limitations by study type were applied to the search, the 
aim was to identify all literature] 
 
Search 1.2: Additional search for clinical review 
An additional search was conducted following inspection of the retrieved articles from the initial search (1.1) 
and identification of further search terms (snowballing). 
1 trauma system$.tw.  [Term utilized from Search 1.1, extended to .tw (Text Word) from .ti,ab (Title or 
Abstract).  NB Text Word searches all of the fields which contain text words and which are appropriate for a 
subject search.] 
2 trauma cent$.tw. [Term utilized from Search 1.1, extended to .tw (Text Word) from .ti (Title)] 
3 Trauma Centers/ [MesH expanded from Search 1.1 by removing *Focus] 
4 1 or 2 or 3 
5 non trauma cent$.tw. 
6 nontrauma cent$.tw. 
7 (without adj2 trauma cent$).tw. 
8 (no adj2 trauma cent$).tw. 
9 non trauma system$.tw. 
10 nontrauma system$.tw. 
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11 (without adj2 trauma system$).tw. 
12 (no adj2 trauma system$).tw. 
13 Major Trauma Outcome Study.tw. 
14 MTOS.tw. 
15 Trauma Injury Severity Score.tw. 
16 TRISS.tw. 
17 (Trauma Audit and Research Network).tw. 
18 TARN.tw.  [Terms 5-18 added following analysis of references retrieved from initial search] 
19 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 
20 4 and 19 
21 (sever$ adj3 injur$).tw.  [Term extended from Search 1.1 by adding truncation ADJ operator 
and .tw (Text Word) instead of .ti (Title)] 
22 (sever$ adj3 trauma$).tw.  [Term extended from Search 1.1 by adding truncation ADJ 
operator and .tw (Text Word) instead of .ti (Title)] 
23 (serious$ adj3 injur$).tw. 
24 ISS.tw.  [Terms 23-24 added following analysis of references retrieved from initial search] 
25 21 or 22 or 23 or 24 
26 1 and 25 
27 20 or 26 
28 Stroke/  [MesH expanded from Search 1.1 by removing *Focus] 
29     stroke.tw.  [Term extended from Search 1.1 by searching .tw (Text Word) instead of .ti,ab (Title or 
Abstract).  Note that truncation was removed for this search] 
30     Cerebral Infarction/ [MesH expanded from Search 1.1 by removing *Focus] 
31     cerebral infar$.tw.  [Term utilized from Search 1.1, extended to .tw (Text Word) from .ti,ab (Title or 
Abstract).   
32     cerebrovascular accident$.tw.  [Term utilized from Search 1.1, extended to .tw (Text Word) from .ti,ab 
(Title or Abstract).   
33     cerebrovascular event$.tw.  [Terms added following analysis of references retrieved from initial 
search] 
34     CVA.tw.  [Term utilized from Search 1.1, extended to .tw (Text Word) from .ti,ab (Title or Abstract).   
35    (intracranial adj (haemorrhage or hemorrhage or bleed$ or haematoma or hematoma)).tw.  [Term 
extended from Search 1.1 by adding truncation, haematoma/hematoma terms, and .tw (Text Word) instead of 
.ti (Title)] 
36     Intracranial Hemorrhages/ 
37     Cerebral Hemorrhage/ 
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38     Subarachnoid Hemorrhage/  [Terms 36-38 extended from Search 1.1 by removing *Focus from MeSH 
headings] 
39     cerebral hemorrhage.tw. 
40     cerebral haemorrhage.tw. 
41     subarachnoid hemorrhage.tw. 
42     subarachnoid haemorrhage.tw.  [Terms 39-42 added following analysis of references retrieved from 
initial search] 
43     Craniocerebral Trauma/ 
44 Brain Injuries/  [Terms 43-44 extended from Search 1.1 by removing *Focus from MeSH 
headings] 
45 Head Injuries, Closed/ [MeSH heading added following analysis of references retrieved from 
initial search] 
46 head injur$.tw.  [Term utilized from Search 1.1, extended to .tw (Text Word) from .ti,ab (Title 
or Abstract).   
47 craniocerebral trauma$.tw.  [Term utilized from Search 1.1, extended to .tw (Text Word) from 
.ti,ab (Title or Abstract).   
48 brain injur$.tw. (25286)  [Term utilized from Search 1.1, extended to .tw (Text Word) from 
.ti,ab (Title or Abstract).   
49 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 
44 or 45 or 46 or 47 or 48 
50 (stroke adj (cent$ or unit$ or hospital$ or facilit$)).tw. 
51 (regional adj2 (cent$ or unit$ or hospital$ or facilit$)).tw. 
52 (speciali$ adj2 (cent$ or unit$ or hospital$ or facilit$)).tw. 
53 (tertiary adj2 (cent$ or unit$ or hospital$ or facilit$)).tw. 
54 Trauma Centers/ 
55 trauma cent$.tw. 
56  (neurosurgical adj2 (cent$ or unit$ or hospital$ or facilit$)).tw. 
57 (critical care adj (cent$ or unit$ or hospital$ or facilit$)).tw. 
58 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 
59 transport$.tw. 
60      transfer$.tw.  [Terms 50-60 added following analysis of references retrieved from initial search] 
61     59 or 60 
62     49 and 58 and 61 
63     27 or 62 
64     limit 63 to yr="1988 -Current"  [Note that no limitations by study type were applied to the search, the 
aim was to identify all literature] 
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Search 1.3 Update search (October-November 2012) 
The search strategy below amalgamates searches 1.1 and 1.2 above into one strategy.  Some terms were 
adapted following examination of the included studies from the original searches as noted below. 
1     (hospital$ adj bypass$).mp. 
2     (direct$ adj3 transfer$).mp. [Term extended by adding truncation ($) and broadening proximity operator 
(adj3 =  terms appear within 3 words of each other)] 
3     (bypass$ adj3 protocol$).mp. [Term extended by adding truncation ($) and broadening proximity 
operator (adj3 =  terms appear within 3 words of each other)] 
4     trauma system$.ti,ab.  
5     or/1-4  
6     Trauma Centers/  
7     trauma cent$.tw.  
8     (stroke adj (cent$ or unit$ or hospital$ or facilit$)).tw.  
9     (regional adj2 (cent$ or unit$ or hospital$ or facilit$)).tw.  
10     (speciali$ adj2 (cent$ or unit$ or hospital$ or facilit$)).tw.  
11     (tertiary adj2 (cent$ or unit$ or hospital$ or facilit$)).tw.  
12     (neurosurgical adj2 (cent$ or unit$ or hospital$ or facilit$)).tw.  
13     (critical care adj (cent$ or unit$ or hospital$ or facilit$)).tw.  
14     or/6-13  
15     *Triage/  
16     triage.ti,ab.  
17     "Transportation of Patients"/ae, ec, st, ut  
18     Patient Transfer/ec, mt, og, st, ut, sn  
19     transfer$.ti,ab.  
20     or/15-19  
21     14 and 20  
22     (prehospital adj triage).mp.  
23     (pre-hospital adj triage).mp.  
24     regionali?ation.ti,ab.  
25     (direct$ adj5 transport$).ti,ab.  
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26     (direct$ adj5 admi$).ti,ab.  
27     or/22-26  
28     5 or 21 or 27  
29     *Multiple Trauma/  
30     trauma.ti,ab.  
31     severe traumatic injur$.ti,ab.  
32     (sever$ adj3 injur$).ti,ab.  
33     (serious$ adj3 injur$).ti,ab.  
34     ISS.ti,ab.  
35     critical$ ill$.ti,ab.  
36     severe emergenc$.ti,ab.  
37     *Critical Care/sn [Statistics & Numerical Data]  
38     Stroke/  
39     stroke$.ti,ab.  
40     Cerebral Infarction/  
41     cerebral infar$.ti,ab.  
42     cerebrovascular accident$.ti,ab.  
43     CVA.ti,ab.  
44     cerebrovascular event$.tw.  
45     Craniocerebral Trauma/  
46     head injur$.ti,ab.  
47     craniocerebral trauma$.ti,ab.  
48     Brain Injuries/  
49     brain injur$.ti,ab.  
50     ((intracranial or inta-cranial) adj (haemorrhage or hemorrhage or bleed$ or haematoma or 
hematoma)).tw.  
51     Intracranial Hemorrhages/ or Cerebral Hemorrhage/ or Subarachnoid Hemorrhage/  
52     *Hematoma, Epidural, Cranial/  
53     cerebral hemorrhage.tw.  
54     cerebral haemorrhage.tw.  
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55     subarachnoid hemorrhage.tw.  
56     subarachnoid haemorrhage.tw.  
57     Head Injuries, Closed/  
58     or/29-57  
59     28 and 58  
60     limit 59 to yr="2010 -Current" [Publication date limit applied to identify studies published since 
original searches were conducted] 
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Appendix III. Study characteristics 
Study Dates, country 
(area), N centres 
N patients Inclusion/exclusion; 
definitions of groups 
Severity 
(inclusion) 
Severity (baseline): 
NIHSS 
Age Data source System co-
ordination 
Description of centres Pre-hospital 
care 
Adjustments 
Thrombolysed only (transfers had tPA in NSC) 
Rodriguez 
201214 
2008-2009 
USA (Minnesota) 
N centres NR 
Total: 602 
A: 473 
B: 129 
Thrombolysed only  
 
A: Direct to SC, tPA at SC 
B: tPA in NSC then 
transferred to SC within 24 
hours 
No cut-off NR NR Minnesota 
Hospital 
Association data. 
Statewide 
sample. 
NR 
 
SC: Comprehensive 
stroke centre 
NSC: Community 
hospitals 
NR NR 
Hsia 201115 2005-2009 
Country NR 
2 SCs, NSCs 
Total: 285 
A: 194 
B: 91 
Thrombolysed only  
 
A: Direct to SC, tPA at SC 
B: tPA in NSC then 
transferred to SC 
 
Note: 100% SC patients but 
only 90% NSC patients had 
discharge diagnosis of 
ischaemic stroke 
No cut-off NIHSS (mean, SD) 
A: 13.5 (NR) 
B: 11.3 (NR) 
Mean (SD): 
A: 71 (NR) 
B: 64 (SD) 
SC database 
(consecutive) 
 
Retrospective 
analysis of 
prospective 
registry 
NR SC: Regional stroke 
centres 
NSC: Community 
hospitals 
NR None. 
Martin-Schild 
201128 
2004-2007 
USA (Houston, 
Texas) 
1 SC, 37 NSCs 
Total:396 
A: 312 
B: 84 
 
Thrombolysed only (within 
3h) 
 
A: Direct to SC, tPA at SC  
B: tPA in NSC then 
transferred to SC 
No cut-off NIHSS (mean, SD): 
A: 13.1 (6.7) 
B: 10.7 (5.8) 
Mean (SD): 
A: 65 (15) 
B: 65 (15) 
Medical records 
at SC and NSC 
 
Retrospective  
Stroke network, 
telemedicine / 
telephone 
SC: Regional stroke 
unit, stroke team 
available 24 hours per 
day 
NSC: Regional and 
other hospitals 
 
Investigator based at SC 
NR None in primary 
analyses 
Pervez 201016 2003-2008 
USA (Boston, 
Massachusetts) 
1 SC, 33 NSCs 
Total: 296 
A: 115 
B: 181 
Thrombolysed only (within 
3h) 
 
A: tPA in SC, may have first 
visited NSC 
B: tPA started in NSC then 
transferred to SC 
No cut-off NIHSS (median, 
IQR): 
A: 12 (8-19) 
B 13 (7-18) 
 
NIHSS >20: 
A: 26/115 (22.6%) 
B: 21/181 (11.6%) 
Mean (SD): 
A: 74 (12) 
B: 72 (15) 
SC database 
 
Prospective 
Stroke network; 
telemedicine / 
telephone 
SC: Regional stroke 
centre 
NSC: Outlying 
hospitals 
 
Investigator based at SC 
NR mRS analysis only: 
Age, NIHSS, time to 
tPA, follow-up time 
Allibert 200917 2003 onwards 
France (Besancon) 
1 SC, NSCs 
Total: 100 
A: 54 
B: 46 
Thrombolysed only (within 
3h or based on MRI) 
 
A: tPA in SC, some first 
visited NSC 
B: tPA in NSC then 
transferred to SC 
No cut-off NR NR NR Stroke network; 
telemedicine 
SC: Stroke unit 
NSC: Distant hospitals 
 
Investigator based at SC 
NR None 
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Study Dates, country 
(area), N centres 
N patients Inclusion/exclusion; 
definitions of groups 
Severity 
(inclusion) 
Severity (baseline): 
NIHSS 
Age Data source System co-
ordination 
Description of centres Pre-hospital 
care 
Adjustments 
Silva 200918 2003-2005 
USA (Massachusetts 
& San Francisco) 
2 SCs, NSCs 
Total: 119 
A: 92 
B: 27  
Thrombolysed only 
 
A: tPA in SC, may have first 
visited NSC 
B: tPA started in NSC then 
transferred to SC 
No cut-off NIHSS (mean, SD): 
A:  12.6 (6.1) 
B: 13.7 (6.4) 
Mean (SD): 
A: 70 (18) 
B: 70 (17) 
Other study 
 
Prospective 
NR SC: Stroke centres at 
university hospitals 
NSC: Community 
hospitals 
 
Investigator based at SC 
NR None 
Wang 200019 1996-1998 
USA (Illinois 
counties) 
1 SC, 13 NSCs 
Total: 57 
A: 23 
B: 34 
Thrombolysed only 
 
A: tPA in SC, may have first 
visited NSC 
B: tPA in NSC then 
transferred to SC 
No cut-off NIHSS (mean, SD): 
A: 15.5 (7.0) 
B: 13.7 (6.4) 
Mean (SD): 
A: 71 (10) 
B: 72 (11) 
Medical records 
(consecutive) 
Stroke network; 
telemedicine / 
telephone 
SC: 730-bed tertiary 
care centre with stroke 
unit, full stroke 
provision 
NSC: Community 
hospitals (68-350 beds) 
 
Investigator based at SC 
 
To SC: 
2 helicopters, 2 
Life Flight 
teams 
None 
Thrombolysed only (transfers had tPA in NSC or SC) 
Rymer 2005,20 
Rymer 200421 
2000-2003 
USA (Kansas City, 
Missouri) 
1 SC, 47 NSCs 
Total: 220 
A: 62 
B: 158 
Thrombolysed only (within 
3h) 
 
A: Direct to SC, tPA in SC 
B: 50% tPA in NSC then 
transferred to SC; 50% tPA 
in SC after transfer 
No cut-off NIHSS >20: 
A: 13/62 (21.0%) 
B: 45/158 (28.5%) 
NR SC database Stroke network, 
telephone 
SC: Regional stroke 
centre, neurologist on-
call, no resident 
neurology cover 
NSC: Community 
hospitals (15-586 beds) 
 
Investigator based at SC 
NR None 
Thrombolysed only (transfers had tPA in SC) 
Perez de la Ossa 
200922 
2005-2007 
Spain (Barcelona) 
1 SC, 4 NSCs 
Total: 153 
A: 108 
B: 45 
Thrombolysed only 
 
A: Direct to SC, tPA in SC 
B: tPA in SC after transfer 
No cut-off NIHSS (median, 
IQR): 
A: 12 (7-18) 
B: 9 (6-15) 
Mean (SD): 
A: 66 (13) 
B: 65 (9) 
SC database 
(consecutive) 
 
Retrospective 
analysis of 
prospective 
registry 
Stroke network SC: Stroke unit, 
neurologic attention at 
all times 
NSC: Community 
hospitals, no specific 
stoke treatment 
 
Investigator based at SC 
and NSC 
 
 
NR mRS analysis only: 
NIHSS, prebolus 
glycaemia, history of 
atrial fibrillation 
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Study Dates, country 
(area), N centres 
N patients Inclusion/exclusion; 
definitions of groups 
Severity 
(inclusion) 
Severity (baseline): 
NIHSS 
Age Data source System co-
ordination 
Description of centres Pre-hospital 
care 
Adjustments 
Ribo 200823 2006 
Spain (Catalunya) 
1 SC, 4 NSCs 
Total: 88 
A: 61 
B: 27 
Thrombolysed only (within 
6h), stroke code activated 
 
A: Direct to SC, tPA in SC 
B: tPA in SC after transfer 
No cut-off NIHSS (median, 
IQR): 
A: 16 (9-19) 
B: 17 (12-20) 
Mean (SD): 
A: 69 (15) 
B: 70 (14) 
NR Stroke network, 
telephone 
SC: Major university 
referral stroke centre 
NSC: Community 
hospitals; no 
neurologist on call, no 
thrombolysis or stroke 
unit 
 
Unclear whether 
investigator based at SC 
or NSC 
 
 
 
 
NR None 
Merino 200224 1998-2000 
USA (London, 
Ontario) 
2 SCs, 33 NSCs 
Total: 72 
A: 49 
B: 23 
Thrombolysed only (90% 
within 3h) 
 
A: Direct to SC, tPA in SC 
B: tPA in SC after transfer 
(only transferred if expected 
to arrive at SC within 3h) 
No cut-off NIHSS (median, 
IQR): 
A: 13 (10 to 19) 
B: 14 (9 to 16) 
Mean (SD): 
A: 73 (10) 
B: 70 (11) 
SC data 
collection 
 
Prospective 
Stroke network SC: Academic medical 
centres, stroke teams, 
24-hour CT and MRI 
NSC: Rural hospitals; 
most lack intensive 
care, CT and 
emergency access to 
stroke physicians 
 
Unclear whether 
investigator based at SC 
or NSC 
 
 
 
 
NR None 
Some thrombolysed, arrived at SC within 4-6h of onset in 2 of 3 studies (transfers had tPA in SC if at all) 
Li 200825 2005 
Taiwan (Kaohsiung) 
1 SC, NSCs 
Total: 101 
A: 85 
B: 16 
Arrived SC within 4h of 
onset; 12% had tPA (NR per 
group) 
 
A: Direct to SC; tPA in SC if 
at all 
B: tPA in SC after transfer if 
at all 
No cut-off NIHSS (mean, SD): 
A+B: 11.8 (9.5) 
Mean (SD): 
A+B: 68 
(12) 
SC stroke code 
activation 
 
Prospective, 
consecutive 
NR SC: Neurology 
department, university 
hospital 
NSC: Other hospitals 
Investigator based at SC 
NR None 
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Study Dates, country 
(area), N centres 
N patients Inclusion/exclusion; 
definitions of groups 
Severity 
(inclusion) 
Severity (baseline): 
NIHSS 
Age Data source System co-
ordination 
Description of centres Pre-hospital 
care 
Adjustments 
Perez de la Ossa 
200826 
2004-2006 
Spain (Barcelona) 
1 SC, 4 NSCs 
Total: 262 
A: 57 
B: 112 
Arrived SC within 6h of 
onset; 40% had tPA 
 
A: Direct to SC, tPA in SC if 
at all (54% had tPA) 
B: tPA in SC after transfer if 
at all (27% had tPA) 
No cut-off NIHSS (median, 
IQR): 
A: 11 (6 to 18) 
B: 5 (3 to 11) 
Mean (SD): 
A: 64 (11) 
B: 67 (10) 
SC data 
collection 
 
Prospective, 
consecutive 
Stroke network SC: Stroke unit, 
neurologic attention 
available at all times 
NSC: Community 
hospitals, no specific 
stoke treatment 
Investigator based at SC 
and NSC 
NR mRS analysis only: 
Age, stroke severity 
Muller 200727 2003-2004 
Germany (Munich 
& Regensburgh) 
4 SCs, 12 NSCs 
Total: 39 
A: 23 
B: 16 
Basilar artery occlusion 
only; 46% had tPA (A: 48%, 
B: 44%) 
 
A: Direct to SC, tPA at SC 
(48% had tPA) 
B: tPA at SC (44% had tPA) 
No cut-off NR Mean (SD): 
A: 68 (16) 
B: 63 (15) 
SC database Stroke network, 
telemedicine 
SC: Academic stroke 
centres, stroke and 
intensive care units, 
neurologic attention at 
all times 
NSC: General hospitals, 
no interventional 
facilities 
Unclear whether 
investigator based at SC 
or NSC 
NR None 
Abbreviations: CT=computed tomography;IQR=interquartile range; MRI=magnetic resonance imaging; mRS=modified Rankin Scale; NIHSS=National Institutes of Health Stroke Scale; 
NR=not reported; NSC=non-specialist centre; SC=specialist centre; SD=standard deviation; telemedicine / telephone = telemedicine / telephone contact available between SC and NSCs; 
tPA=tissue plasminogen activator (thrombolysis). Definitions of study groups: A=direct to SC and remained there; B=to NSC initially then transferred to SC. 
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Appendix IV. Risk of bias in included studies 
Study Comparability between 
groups: Risk of bias due to 
lack of inclusion of, or 
adjustment for, NSC patients 
not transferred to SC 
Adjustment: Risk of bias 
due to lack of adjustment 
of analyses for differences 
in age and severity between 
groups 
Representative sample: Risk 
of bias due to selection of 
patients based on condition 
subtype or interventions 
received 
Exclusions: Risk of 
bias due to more than 
5% patients excluded 
due to missing data 
Thrombolysed only (transfers had tPA in NSC) 
Rodriguez 201214 High risk High risk High risk (thrombolysed only) Unclear 
Hsia 201115 High risk High risk High risk (thrombolysed only) Low risk (0%) 
Martin-Schild 201128 High risk High risk High risk (thrombolysed only) Unclear 
Pervez 201016 High risk Low risk High risk (thrombolysed only) Low risk (0%) 
Allibert 200917 High risk High risk High risk (thrombolysed only) Low risk (0%) 
Silva 200918 High risk High risk High risk (thrombolysed only) Unclear 
Wang 200019 High risk High risk High risk (thrombolysed only) Low risk (0%) 
Thrombolysed only (transfers had tPA in NSC or SC) 
Rymer 2005,20 Rymer 
200421 
High risk High risk High risk (thrombolysed only) Low risk (0%) 
Thrombolysed only (transfers had tPA in SC) 
Perez de la Ossa 200922 High risk Low risk High risk (thrombolysed only) Unclear 
Ribo 200823 High risk High risk High risk (thrombolysed only) Low risk (0%) 
Merino 200224 High risk High risk High risk (thrombolysed only) Low risk (0%) 
Some thrombolysed, arrived at SC within 4-6h of onset in 2 of 3 studies (transfers had tPA in SC if at all) 
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Study Comparability between 
groups: Risk of bias due to 
lack of inclusion of, or 
adjustment for, NSC patients 
not transferred to SC 
Adjustment: Risk of bias 
due to lack of adjustment 
of analyses for differences 
in age and severity between 
groups 
Representative sample: Risk 
of bias due to selection of 
patients based on condition 
subtype or interventions 
received 
Exclusions: Risk of 
bias due to more than 
5% patients excluded 
due to missing data 
Li 200825 High risk High risk High risk (arrived within 
thrombolysis time window) 
Low risk (0%) 
Perez de la Ossa 200826 High risk Low risk High risk (arrived within 
thrombolysis time window) 
Low risk (0%) 
Muller 200727 High risk High risk High risk (basilar artery 
occlusion only) 
Low risk (0%) 
Abbreviations: NSC=non-specialist centre; SC=specialist centre; tPA=tissue plasminogen activator (thrombolysis).  
 
